The Cleveland Cardiometabolic Cohort
Observational Study of Cardiometabolic Risk in HIV Infected Subjects After Initiation of Antiretroviral Therapy: The Cleveland Cardiometabolic Cohort
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Danielle Labbato, BSN
- Phone Number: 216-844-2739
- Email: danielle.labbato@uhhospitals.org
Study Contact Backup
- Name: Grace McComsey, MD
- Email: mccomsey.grace@clevelandactu.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
- Provides written informed consent and is capable of reading and comprehending the informed consent
- Is not currently taking antiretroviral therapy and has never been on such treatments in the past. Exception would be for subjects who had been in the past on ≤30 days cumulative antiretrovirals, as long as these were stopped >6 months prior to study entry
- Is planning on starting antiretroviral therapy as part of routine clinic care
Exclusion Criteria:
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HIV-infected ART-naïve
HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body composition measures
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Assessed using DEXA (dual energy x-ray absorptiometry) scans which will be quantifying total body fat
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Resting Energy Expenditure (REE) measures
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Assessed using a BodyGem REE calculator (values in KCal)
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
|
endothelial function measures
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Assessed using EndoPAT (values reported as a reactive hyperemia index RHI)
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
|
calcium score measures
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Assessed using CT scans
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
|
central obesity
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
measured with waist circumference using a tape measure (in cm)
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
|
Lipids measures
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
used measuring blood levels of triglycerides (mg/dL); serum high-density lipoprotein (mg/dL) ; cholesterol (mg/dL); low density lipoprotein (mg/dL)
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
|
Fasting plasma glucose measures
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
fasting plasma glucose test is performed after a person has fasted for at least 8 hours (measured in mg/dL)
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
|
Metabolic syndrome
Time Frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Metabolic syndrome will be defined using the following measures: central obesity, serum triglycerides , serum high-density lipoprotein (HDL); cholesterol levels and fasting plasma glucose
|
Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Grace McComsey, MD, University Hospitals Cleveland Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Skin Diseases
- Lipid Metabolism Disorders
- Skin Diseases, Metabolic
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- Lipodystrophy
- Investigative Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Diagnostic Imaging
- Chemistry Techniques, Analytical
- Radiography
- Densitometry
- Photometry
- Absorptiometry, Photon
Other Study ID Numbers
Other Study ID Numbers
- 06-16-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
NCT07218211RecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis Use
-
NCT07618507Completed
-
NCT05384145RecruitingHIV | HIV Testing | HIV Linkage to Care | HIV Treatment
-
NCT07509827RecruitingHIV Prevention | PrEP Adherence | HIV Related Stigma
-
NCT07231640RecruitingPrEP | HIV | HIV Prevention | PrEP Uptake
-
NCT07656077Not yet recruitingAntiretroviral Therapy | HIV-1 Infection | HIV Reservoir
-
NCT07194902RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum Women
-
NCT02570334UnknownHIV | HIV-uninfected Children | Children Exposed to HIV
-
NCT01494961CompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV Incidence
-
NCT04144335WithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and Infections
Clinical Trials on Dual-energy X-ray absorptiometry
-
NCT06902597Recruiting
-
NCT01618149UnknownPeriprosthetic Bone Loss in Total Knee Replacement
-
NCT02435251WithdrawnShoulder Surgery | Knee Surgery
-
NCT04535180CompletedHemophilia | Sarcopenia | Hemophilic Arthropathy | Osteoporosis, Osteopenia
-
NCT02806154Completed
-
NCT06818591CompletedOsteoporosis | HELICOBACTER PYLORI INFECTIONS